Emilio Clementi

Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”

C. Perrotta, D. Cervia, M. Pozzi, 2023, Vaccines.

The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions

E. Clementi, M. Molteni, D. Cattaneo, 2017, The Pharmacogenomics Journal.

The first steps towards the era of personalised vaccinology: predicting adverse reactions

E. Clementi, S. Radice, C. Perrotta, 2014, The Pharmacogenomics Journal.

Neurological and psychiatric adverse events with prucalopride: case report and possible mechanisms

E. Clementi, S. Radice, V. Perrone, 2013, Journal of clinical pharmacy and therapeutics.

Two Years of Active Pharmacovigilance Surveillance and Therapeutic Reconciliation in Frail Populations: The MEAP 3.0 Study

G. Crescioli, S. Radice, C. Rafaniello, 2023, Journal of clinical medicine.

Epidemiological analysis on two decades of hospitalisations for meningitis in the United States

E. Clementi, S. Radice, V. Perrone, 2014, European Journal of Clinical Microbiology & Infectious Diseases.

Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues

C. Carnovale, V. Battini, Emilio Clementi, 2024, Journal of neurology.

Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study

E. Poluzzi, E. Raschi, F. De Ponti, 2022, Psychiatry and clinical neurosciences.

Exposure to environmental pollutants and attention-deficit/hyperactivity disorder: an overview of systematic reviews and meta-analyses

M. Pozzi, M. Mauri, E. Rosi, 2023, Environmental Science and Pollution Research.